Precision Medicine And The Advent Of The “Niche Buster”: An Interview With GSK’s Paolo Paoletti

21 Jan 2013

• By Shirley Haley

The president of GlaxoSmithKline Oncology talked with “The Pink Sheet” about precision medicine, regulatory climate change, the need to provide value for payers and the company’s commitment to double cancer survival globally over the next 10 years.

Precision Medicine And The Advent Of The “Niche Buster”: An Interview With GSK’s Paolo Paoletti

More from Government Payers

More from Market Access